Cancer of Lung
Health Information Search Results
Peer Reviewed Scientific Research Reports.
|<< Prev 20 ||Showing 1 to 20 of 68 Matches||Next 20 >>|
1. Risk factors for lung cancer in patients with scleroderma: A nested case-control study.
Match Strength: 8.962
OBJECTIVE: To study potential risk factors for the development of lung cancer in scleroderma patients and explore the chronological relationship between onset of scleroderma symptoms and subtypes of lung cancer. METHOD: Linkage of two population based registers to identify lung cancer cases and gender-matched controls with scleroderma, followed by retrospective case note review for clinical details. RESULTS: Patients with scleroderma who smoke are 7 times more likely to develop lung cancer than non- smokers (p=0.008). Scleroderma smokers with cancer smoke more than scleroderma smokers without ... Read More »
» Published in Ann Rheum Dis. 2006 Sep 19;
2. Family history and risk of lung cancer: age-at-diagnosis in cases and first-degree relatives.
Match Strength: 8.200
To investigate the little known risk of lung cancer at an early age when a first-degree relative has had such a diagnosis, 579 incident cases and 1157 population controls were studied in Liverpool between 1998 and 2004 using standardised questionnaires covering demography and lifestyle. A history of lung cancer in first-degree relatives was associated with a significantly increased risk in the proband where in both individuals the cancers were diagnosed before the age of 60 years (odds ratio (OR)=4.89; 95% confidence interval (CI): 1.47-16.25). A significantly elevated risk of lung cancer was ... Read More »
» Published in Br J Cancer. 2006 Nov 6;95(9):1288-90. Epub 2006 Sep 26.
3. Percutaneous radiofrequency thermal ablation of primary and metastatic lung tumors.
Match Strength: 7.126
OBJECTIVE: Primary lung cancer is the leading cause of death from cancer. For patients with inoperable lung cancer, percutaneous radiofrequency thermal ablation (RFA) under CT-guidance represents a minimally invasive treatment. It can also be applied in combination with radiation therapy and chemotherapy. MATERIALS AND METHODS: In a period of 18 months, RFA under CT-guidance 27 ablations were applied on 22 patients, 14 patients with primary lung cancer and 8 patients with metastatic lung tumor. There were 15 men and 7 women ranging in age between 48 and 79 years. All patients were not surgical ... Read More »
» Published in Eur J Cardiothorac Surg. 2006 Nov;30(5):797-800. Epub 2006 Sep 26.
4. Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications.
Match Strength: 6.691
The discovery that mutation of the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene occurs in a subset of lung cancers and predicts for sensitivity to tyrosine kinase inhibitors has generated enormous interest and immediately led to intense basic, translational, and clinical research in many laboratories around the globe. All these findings have led to the identification of a subset of lung cancers with relatively distinct molecular, pathologic, and clinical features that demonstrate response to targeted therapy. Currently, the best marker to predict response and ... Read More »
» Published in Ann Diagn Pathol. 2006 Oct;10(5):306-15.
5. Modelling smoking history using a comprehensive smoking index: application to lung cancer.
Match Strength: 6.675
The mathematical representation of smoking history is an important tool in analysis of epidemiological and clinical data. Hoffmann and colleagues recently proposed a single aggregate measure of smoking exposure that incorporates intensity, duration, and time since cessation. This comprehensive smoking index (CSI), which may be incorporated in any regression model, depends on a half-life (tau) and a lag (delta) parameters that have to be fixed a priori, or estimated by maximizing the fit. The CSI has not previously been used for analysis of cancer data. Following some preliminary results on ... Read More »
» Published in Stat Med. 2006 Dec 30;25(24):4132-46.
6. Radical sublobar resection for small-sized non-small cell lung cancer: a multicenter study.
Match Strength: 6.473
OBJECTIVE: At present, even when early-stage, small-sized non-small cell lung cancers are being increasingly detected, lesser resection has not become the treatment of choice. We sought to compare sublobar resection (segmentectomy or wedge resection) with lobar resection to test which one is the appropriate procedure for such lesions. METHODS: From 1992 to 2001, a nonrandomized study was performed in 3 institutes for patients with a peripheral cT1N0M0 non-small cell lung cancer of 2 cm or less who were able to tolerate a lobectomy. The results of the sublobar resection group enrolled ... Read More »
» Published in J Thorac Cardiovasc Surg. 2006 Oct;132(4):769-75.
7. Disturbance of systemic antioxidant profile in nonsmall cell lung carcinoma.
Match Strength: 6.445
The present study aimed to determine the alterations of antioxidant activities in erythrocytes from patients with nonsmall cell lung carcinoma (NSCLC). A comparative study of the systemic antioxidant activities in red blood cell lysate from subjects with NSCLC and healthy control subjects was conducted. The antioxidants catalase, superoxide dismutase (SOD) and glutathione peroxidase (GPx) were measured using chemical kinetic reactions under spectrophotometry. In total, 189 cases of mostly advanced-stage IIIB or stage IV NSCLC and 202 healthy controls were studied. In subjects with lung cancer, ... Read More »
» Published in Eur Respir J. 2007 Feb;29(2):273-8. Epub 2006 Sep 27.
8. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.
Match Strength: 6.337
PURPOSE: Small-cell lung cancer (SCLC) is a histologic subtype of lung cancer with a distinct biology and clinical course. It has been observed that the incidence of SCLC has been decreasing over the last several years. METHODS: We used the Surveillance, Epidemiologic, and End Results (SEER) database to determine the incidence of SCLC over the last 30 years. In addition, we sought to determine sex- and stage-based differences in the incidence and survival of SCLC among a proportion of reported cases of lung cancer over the last 30 years (1973 to 2002). Joinpoint analyses were applied to test ... Read More »
» Published in J Clin Oncol. 2006 Oct 1;24(28):4539-44. Comment in: J Clin Oncol. 2006 Oct 1;24(28):4526-7.
9. Population-based study of the prevalence of family history of cancer: implications for cancer screening and prevention.
Match Strength: 6.278
PURPOSE: Family history assessment is gaining importance as a potential public health tool to help determine susceptibility to common cancers. Population-based data on the prevalence of having a family history of common cancers are scant. METHODS: We queried survey questions from the National Health Interview Survey, an annual nationwide survey of approximately 36,000 households in the United States, to determine the prevalence of persons reporting one or more first-degree relatives with breast, colorectal, lung, prostate, or ovarian cancer. RESULTS: Breast cancer was the most common condition ... Read More »
» Published in Genet Med. 2006 Sep;8(9):571-5.
10. Incidental findings on integrated PET/CT that do not accumulate 18F-FDG.
Match Strength: 6.169
OBJECTIVE: The purpose of this study was to report the prevalence of abnormalities that do not show increased 18F-FDG uptake on the CT component of integrated PET/CT in patients with non-small cell lung cancer. MATERIALS AND METHODS: Images from all PET/CT studies performed consecutively between April and October 2003 on patients with non-small cell lung cancer were retrospectively reviewed. All abnormalities present on the CT component of the PET/CT scans that did not show abnormally increased 18F-FDG uptake were documented. RESULTS: Three hundred twenty-one patients with non-small cell lung ... Read More »
» Published in AJR Am J Roentgenol. 2006 Oct;187(4):1116-23.
11. Development of an orthotopic transplantation model in nude mice that simulates the clinical features of human lung cancer.
Match Strength: 6.144
The objective of the present study was to establish an orthotopic tumor transplantation model in nude mice that closely resembles the clinical features of human lung cancer. The human lung adenocarcinoma A549 cell line and the squamous cell carcinoma SQ5 cell line were used. Tumor cells suspended in serum-free medium were injected directly into the main bronchi of anesthetized female Balb/c athymic nude mice (7-9 weeks old) with or without simultaneous administration of 0.01 M ethylenediaminetetracetic acid (EDTA). In some experiments, lung carcinoma cells harvested from tumors transplanted ... Read More »
» Published in Cancer Sci. 2006 Oct;97(10):996-1001.
12. Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT).
Match Strength: 5.784
PURPOSE: To investigate factors associated with treatment-related pneumonitis in non-small-cell lung cancer patients treated with concurrent chemoradiotherapy. PATIENTS AND METHODS: We retrospectively analyzed data from 223 patients treated with definitive concurrent chemoradiotherapy. Treatment-related pneumonitis was graded according to Common Terminology Criteria for Adverse Events version 3.0. Univariate and multivariate analyses were performed to identify predictive factors. RESULTS: Median follow-up was 10.5 months (range, 1.4-58 months). The actuarial incidence of Grade > or =3 ... Read More »
» Published in Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1399-407. Epub 2006 Sep 25.
13. Stabilization of membrane bound enzyme profiles and lipid peroxidation by Withania somnifera along with paclitaxel on benzo(a)pyrene induced experimental lung cancer.
Match Strength: 5.697
The present study was aimed to evaluate the therapeutic effects of Withania somnifera along with paclitaxel on lung tumor induced by benzo(a)pyrene in male Swiss albino mice. The levels of ATPase enzymes and lipid peroxidation were evaluated in lung cancer bearing mice, in erythrocyte membrane and tissues. The extent of peroxidation was estimated by measuring the thiobarbituric acid-reactive substances. Simultaneously the activities of different ATPases (Na(+)/K(+)-ATPases, Mg(2+)-ATPases and Ca(2+)-ATPases) were determined. The alterations of these enzyme activities in membrane and tissues ... Read More »
» Published in Mol Cell Biochem. 2006 Nov;292(1-2):13-7. Epub 2006 Sep 27.
14. The prognostic impact of tumor size in resected stage I non-small cell lung cancer: evidence for a two thresholds tumor diameters classification.
Match Strength: 5.661
PURPOSE: The current TNM staging system for non-small cell lung cancer subdivides stage IA and IB according to a tumor size threshold of 3 cm. Some authors have suggested that tumor size behaves as a continuous, but the optimal diameter thresholds to be adopted remain debated. METHODS: We conducted a retrospective study on 548 patients who underwent a complete surgical resection at our institute for stage IA and IB non-small cell lung cancer according to the current TNM staging system. Univariate and multiaviate analysis of overall and disease-specific survival were performed. RESULTS: Stage ... Read More »
» Published in Lung Cancer. 2006 Nov;54(2):185-91. Epub 2006 Sep 22.
15. Suppression of cancer cell migration and invasion by protein phosphatase 2A through dephosphorylation of mu- and m-calpains.
Match Strength: 5.651
The mu- and m-calpains are major members of the calpain family that play an essential role in regulating cell motility. We have recently discovered that nicotine-activated protein kinase C iota enhances calpain phosphorylation in association with enhanced calpain activity and accelerated migration and invasion of human lung cancer cells. Here we found that specific disruption of protein phosphatase 2A (PP2A) activity by expression of SV40 small tumor antigen up-regulates phosphorylation of mu- and m-calpains whereas C2-ceramide, a potent PP2A activator, reduces nicotine-induced calpain ... Read More »
» Published in J Biol Chem. 2006 Nov 17;281(46):35567-75. Epub 2006 Sep 18.
16. Surgically removed thoracolithiasis: report of two cases.
Match Strength: 5.590
Thoracolithiasis is a rare condition with only 12 cases of surgically removed nodules reported in the literature. We report 2 additional cases. Case 1: A 19-year-old male admitted with an abnormal shadow on a chest X-ray. Computed tomography (CT) revealed a nodule in the right lower lung lobe. The material extirpated by thoracoscopy was milky white, glossy, and 1.6 cm in diameter. Histopathologically, it consisted of fatty necrotic tissue covered with hyalinized fibrous tissue. Case 2: A 78-year-old female, with a past history of breast cancer, admitted with an abnormal shadow on chest X-ray. ... Read More »
» Published in Ann Thorac Cardiovasc Surg. 2006 Aug;12(4):279-82.
17. Expression of histo-blood group antigens in bronchial squamous metaplasia.
Match Strength: 5.457
The aim of the present study was to evaluate the expression of blood group antigens in squamous bronchial metaplasia in order to determine whether this factor could identify patients at risk of lung cancer. In total, 100 bronchial biopsies were included in the present study. The cases were classified according to the World Health Organization grading system. Immunohistochemical stains for histo-blood groups A and B, and reactivity tests to p53 and the cellular proliferation index were performed. A total of 56 (56%) patients belonged to blood group A. Among them, six (10.7%) patients who did ... Read More »
» Published in Eur Respir J. 2007 Feb;29(2):268-72. Epub 2006 Sep 27.
18. Accreditation and quality assurance for Radiation Therapy Oncology Group: Multicenter clinical trials using Stereotactic Body Radiation Therapy in lung cancer.
Match Strength: 5.418
Starting in 2002, the Radiation Therapy Oncology Group in North America began the process of developing multicenter prospective trials in lung cancer using Stereotactic Body Radiation Therapy (SBRT). Much of the work was based on the prospective single institution trials from Indiana University that had been presented and published. In late 2004, RTOG 0236 using SBRT for medically inoperable patients with clinical stage I non-small cell lung cancer (NSCLC) was activated for accrual. Prior to activation, representatives from the Lung, Image-Guided Therapy, Physics, and Radiobiology Committees ... Read More »
» Published in Acta Oncol. 2006;45(7):779-86.
19. Quantitative assessment of lung cancer perfusion using MDCT: does measurement reproducibility improve with greater tumor volume coverage?
Match Strength: 5.162
OBJECTIVE: To date, quantitative assessment of tumor vascularity using perfusion CT has been limited to a single tumor level, with the potential for measurement error in heterogeneous tumors. We aimed to determine if greater z-axis tumor coverage improves the reproducibility of perfusion CT measurements in lung cancer. SUBJECTS AND METHODS: Paired perfusion studies were performed on 10 patients who had histologically confirmed advanced non-small cell lung cancer. Using 16-MDCT, multiple sequential volumetric acquisitions encompassing the entire tumor were acquired after infusion of i.v. ... Read More »
» Published in AJR Am J Roentgenol. 2006 Oct;187(4):1079-84.
20. 4D imaging for target definition in stereotactic radiotherapy for lung cancer.
Match Strength: 5.162
Stereotactic radiotherapy of Stage I lung tumors has been reported to result in high local control rates that are far superior to those obtained with conventional radiotherapy techniques, and which approach those achieved with primary surgery. Breathing-induced motion of tumor and target tissues is an important issue in this technique and careful attention should be paid to the contouring and the generation of individualized margins. We describe our experience with the use of 4DCT scanning for this group of patients, the use of post-processing tools and the potential benefits of respiratory ... Read More »
» Published in Acta Oncol. 2006;45(7):966-72.
|<< Prev 20 ||Showing results 1 to 20 of 68||Next 20 >>|
* All information on Level1Diet.com is for educational purposes only. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. Before changing your diet, or adding supplements to your diet, or beginning an exercise program, everyone should consult a qualified and licensed health practitioner; a physician, dietician or similar professional.